Search
                    Hollywood, FL Paid Clinical Trials
A listing of 191  clinical trials  in Hollywood, FL  actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
            133 - 144 of 191
        
                There are currently 191 clinical trials in Hollywood, Florida looking for participants to engage in research studies. Trials are conducted at various facilities, including Memorial Regional Hospital/Joe DiMaggio Children's Hospital, GSK Investigational Site, Memorial Healthcare System and Memorial Cancer Institute at Memorial Regional Hospital. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you. 
            
                                        Featured Trial
                
                Healthy Participants Needed (Colonoscopy + Cancer Screening)
            
        Recruiting
            
        Earn $325 - $475 in electronic payment card compensation for your time and effort by participating in a clinical study to develop a blood test that may one day help screen for colon cancer. Take a quick quiz to see if you qualify.
    
    
                            Conditions: 
                                    
        
            
                        Healthy
                    
                                    
                        Healthy Volunteers
                    
                                    
                        Healthy Subjects
                    
                                    
                        Healthy Volunteer
                    
                                    
                        Healthy Participants
                    
                                    Featured Offer
                
                Lose Weight with GLP-1 Medications
            
        Recruiting
            
        Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to semaglutide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®. 
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $50 off your first program with code policy-lab-50.
    GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $50 off your first program with code policy-lab-50.
                            Conditions: 
                                    
        
            
                        Overweight
                    
                                    
                        Overweight and Obesity
                    
                                    
                        Obesity
                    
                                    
                        Weight Loss
                    
                                    
                        Morbid Obesity
                    
                                    Featured Trial
                
                Stroke Clinical Study
            
        Recruiting
            
        A clinical study for people that suffer with Stroke
    
    
                            Conditions: 
                                    
        
            
                        Stroke
                    
                                    Featured Trial
                
                Chronic Kidney Disease (CKD) Clinical Study
            
        Recruiting
            
        A clinical study for people that suffer with Chronic Kidney Disease (CKD)
    
    
                            Conditions: 
                                    
        
            
                        Chronic Kidney Disease (CKD)
                    
                                    Featured Trial
                
                Ischemic heart disease (IHD) Clinical Study
            
        Recruiting
            
        A clinical study for people that suffer with Ischemic heart disease (IHD)
    
    
                            Conditions: 
                                    
        
            
                        Ischemic heart disease (IHD)
                    
                                    Featured Trial
                
                Cardiovascular Disease Clinical Study
            
        Recruiting
            
        A clinical study for people that suffer with Cardiovascular Disease
    
    
                            Conditions: 
                                    
        
            
                        Cardiovascular Disease
                    
                                    
                
                                    Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab
                                
            
            
        Recruiting
                            
            
                The phase III trial compares the effect of pembrolizumab to observation for the treatment of patients with early-stage triple-negative breast cancer who achieved a pathologic complete response after preoperative chemotherapy in combination with pembrolizumab. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This trial may help researchers determine if observa...  Read More             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                06/24/2025
            
            Locations: Memorial Regional Hospital/Joe DiMaggio Children's Hospital, Hollywood, Florida         
        
        
            Conditions: Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Early Stage Triple-Negative Breast Carcinoma
        
            
        
    
                
                                    ARTEMIS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With a Heart Attack
                                
            
            
        Recruiting
                            
            
                The research study is being done to see if ziltivekimab can be used to treat people who were admitted to hospital because of a heart attack. Ziltivekimab might reduce development of heart disease, thereby preventing new heart attacks or strokes. Participants will either get ziltivekimab (active medicine) or placebo (a dummy medicine which has no effect on the body). Which treatment participants get is decided by chance. The chance of getting ziltivekimab or placebo is the same. The participant w...  Read More             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                06/24/2025
            
            Locations: Memorial Healthcare, Hollywood, Florida         
        
        
            Conditions: Cardiovascular Risk, Acute Myocardial Infarction (AMI)
        
            
        
    
                
                                    Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1)
                                
            
            
        Recruiting
                            
            
                This is a Phase 3, open-label, randomized, clinical trial evaluating the efficacy and safety of gedatolisib plus fulvestrant with or without palbociclib for the treatment of patients with locally advanced or metastatic HR+/HER2- breast cancer following progression on or after CDK4/6 and aromatase inhibitor therapy.             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                06/23/2025
            
            Locations: South Broward Hospital District d/b/a Memorial Healthcare System, Hollywood, Florida         
        
        
            Conditions: Breast Cancer
        
            
        
    
                
                                    A Screening Study to Collect Samples for TAA, HLA & HLA Loss of Heterozygosity in Patients With Metastatic Solid Tumors
                                
            
            
        Recruiting
                            
            
                TScan Therapeutics is developing cellular therapies across multiple solid tumors in which autologous T cells are engineered to express a T cell receptor that recognizes tumor-associated antigens presented on specific Human Leukocyte Antigen (HLA) molecules. The purpose of this screening study is to collect samples to conduct HLA genotyping, HLA Loss of Heterozygosity (LOH) assessment, and expression of Tumor-associated Antigens (TAA) testing. These results will be used to determine if participan...  Read More             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                06/20/2025
            
            Locations: Memorial Healthcare System, Hollywood, Florida         
        
        
            Conditions: Head and Neck Cancer, Cervical Cancer, Non Small Cell Lung Cancer, HPV16 Related Cancers, Sarcoma, Uveal Melanoma, NUT Carcinoma
        
            
        
    
                
                                    RESPONDER-HF Trial
                                
            
            
        Recruiting
                            
            
                Multicenter, Prospective, Randomized, Sham Controlled, Double Blinded Clinical Trial, with; 1:1 randomization             
        
        
    Gender:
                ALL
            Ages:
                40 years and above
            Trial Updated:
                06/19/2025
            
            Locations: Memorial Regional Hospital, Hollywood, Florida         
        
        
            Conditions: Heart Failure, Heart Failure, Diastolic
        
            
        
    
                
                                    Study of Mixed Vaccination Schedules With a 21-valent Pneumococcal Conjugate Vaccine and a 20-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age
                                
            
            
        Recruiting
                            
            
                This study is a Phase 3, randomized, modified double-blind study which aims to measure whether the investigational pneumococcal conjugate vaccine PCV21 is safe and can help the body to develop germ-fighting agents called "antibodies" (immunogenicity) when it is given after 1 dose, 2 doses, or 3 doses of a licensed 20-valent pneumococcal vaccine compared to when 20-valent pneumococcal vaccine is given as a complete series in infants aged from approximately 2 months (42 to 89 days).
The study dur...  Read More             
        
        
    Gender:
                ALL
            Ages:
                Between 42 days and 89 days
            Trial Updated:
                06/13/2025
            
            Locations: The Medici Medical Research- Site Number : 8400008, Hollywood, Florida         
        
        
            Conditions: Pneumococcal Immunization
        
            
        
    
                
                                    Post Approval Study - Evaluate the Long-Term Safety and Effectiveness of the WEB Device
                                
            
            
        Recruiting
                            
            
                A prospective, multicenter, single arm, interventional study. The target patient population for this study are adult subjects with WNBAs of the anterior and posterior intracranial circulation. The primary effectiveness outcome of the study is adequate intracranial aneurysm occlusion on the 1 year angiogram as adjudicated by a core laboratory.             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                06/13/2025
            
            Locations: Memorial Health Systems, Hollywood, Florida         
        
        
            Conditions: Wide Neck Bifurcation Intracranial Aneurysms
        
            
        
    
                
                                    The Diaphragmatic Initiated Ventilatory Assist (DIVA) Trial
                                
            
            
        Recruiting
                            
            
                DIVA is a pragmatic randomized clinical trial (RCT) to determine: among (P) preterm infants born 23 0/7-28 6/7 weeks gestation undergoing extubation from mechanical ventilation, whether (I) Non-invasive neurally adjusted ventilatory assist (NIV-NAVA) (C) compared with Non-synchronized nasal intermittent positive pressure ventilation (NS-NIPPV), will reduce the incidence of (O) extubation failure within (T) 5 days (120 hours) of extubation.             
        
        
    Gender:
                ALL
            Ages:
                Between 0 days and 9 weeks
            Trial Updated:
                06/13/2025
            
            Locations: Joe DiMaggio Children's Hospital, Hollywood, Florida         
        
        
            Conditions: Extubation Failure, Bronchopulmonary Dysplasia, Death
        
            
        
    
                
                                    Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast Cancer
                                
            
            
        Recruiting
                            
            
                The purpose of this study is to compare the effects on low risk breast cancer receiving usual care that includes regional radiation therapy, with receiving no regional radiation therapy. Researchers want to see if not giving this type of radiation treatment works as well at preventing breast cancer from coming back.             
        
        
    Gender:
                FEMALE
            Ages:
                35 years and above
            Trial Updated:
                06/10/2025
            
            Locations: Memorial Regional Hospital/Joe DiMaggio Children's Hospital, Hollywood, Florida         
        
        
            Conditions: Breast Cancer
        
            
        
    
                
                                    Stereotactic Radiosurgery Compared With Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) Plus Memantine for 5 or More Brain Metastases
                                
            
            
        Recruiting
                            
            
                Stereotactic radiosurgery (SRS) is a commonly used treatment for brain tumors. It is a one-day (or in some cases two day), out-patient procedure during which a high dose of radiation is delivered to small spots in the brain while excluding the surrounding normal brain.
Whole brain radiation therapy with hippocampal avoidance (HA-WBRT) is when radiation therapy is given to the whole brain, while trying to decrease the amount of radiation that is delivered to the area of the hippocampus. The hipp...  Read More             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                06/10/2025
            
            Locations: Memorial Regional Hospital/Joe DiMaggio Children's Hospital, Hollywood, Florida         
        
        
            Conditions: Brain Metastases
        
            
        
    
                
                                    Effect of Hepatic Impairment on the Pharmacokinetics and Safety of VIR-2218 and VIR-3434
                                
            
            
        Recruiting
                            
            
                In this study, a single dose of VIR-2218 up to 200 mg SC or VIR-3434 at 300 mg SC monotherapy or a combination of VIR-2218 and VIR-3434 will be administered to assess the pharmacokinetic (PK) exposure, safety, and tolerability of VIR-2218 and VIR-3434 in participants with cirrhosis and Hepatic Impairment, defined using the Child-Pugh-Turcotte (CPT) categorization.             
        
        
    Gender:
                ALL
            Ages:
                Between 18 years and 70 years
            Trial Updated:
                06/10/2025
            
            Locations: CenExel Research Centers of America, Hollywood, Florida         
        
        
            Conditions: Hepatic Impairment, Cirrhosis
        
            
        
    
                
                                    Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Pociredir
                                
            
            
        Recruiting
                            
            
                This is a study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of Pociredir in participants with sickle cell disease.             
        
        
    Gender:
                ALL
            Ages:
                Between 18 years and 65 years
            Trial Updated:
                06/05/2025
            
            Locations: Foundation for Sickle Cell Disease Research, LLC, Hollywood, Florida         
        
        
            Conditions: Sickle Cell Disease, Sickle Cell Anemia
        
            
        
    133 - 144 of 191
            